No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
APGE250117C50000
- 1.80
- -0.20-10.00%
15min DelayTrading Dec 23 10:58 ET
1.80High1.80Low
1.80Open2.00Pre Close1 Volume12 Open Interest50.00Strike Price180.00Turnover69.32%IV8.16%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry1.80Extrinsic Value100Contract SizeAmericanOptions Type0.4254Delta0.0455Gamma19.75Leverage Ratio-0.0700Theta0.0122Rho8.40Eff Leverage0.0487Vega
Intraday
- 5D
- Daily
News
Apogee Therapeutics Director Mark McKenna Acquires $990,775 in Stock
Guggenheim Reiterates Buy on Apogee Therapeuticsto Buy
Apogee Therapeutics Advances Clinical Trials for APG333
Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025
Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, Its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions